Omnicell (NASDAQ:OMCL) Stock Price Down 4.9% – Should You Sell?

Omnicell, Inc. (NASDAQ:OMCL)’s share price dropped 4.9% during mid-day trading on Wednesday . The stock traded as low as $38.89 and last traded at $38.6790. Approximately 59,761 shares changed hands during trading, a decline of 90% from the average daily volume of 602,368 shares. The stock had previously closed at $40.69.

Analysts Set New Price Targets

OMCL has been the topic of several analyst reports. KeyCorp raised their price target on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. UBS Group set a $60.00 price target on shares of Omnicell and gave the stock a “buy” rating in a research note on Friday, March 13th. Wells Fargo & Company raised their price target on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. Finally, Craig Hallum reaffirmed a “buy” rating and set a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $59.86.

Omnicell Price Performance

The company’s 50-day moving average is $40.36 and its 200-day moving average is $41.50. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of 85.96, a PEG ratio of 0.99 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same period last year, the company earned $0.26 earnings per share. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, research analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Insider Activity at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 15,520 shares of company stock worth $607,610 over the last three months. Corporate insiders own 2.92% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OMCL. Raymond James Financial Inc. acquired a new position in Omnicell during the second quarter valued at approximately $26,000. Clearstead Advisors LLC lifted its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in Omnicell during the fourth quarter valued at approximately $58,000. Parkside Financial Bank & Trust lifted its position in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after buying an additional 1,264 shares in the last quarter. Finally, First Horizon Corp lifted its position in Omnicell by 54.6% during the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after buying an additional 564 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.